相关实验视频
Updated: Jun 25, 2025

07:23
Improved Rodent Model of Myocardial Ischemia and Reperfusion Injury
Published on: March 7, 2022
5.9K
在缺血性心脏病中SGLTi的保护机制
Lei Liao1, Tong Wang2, Lu Zhang1
1Department of Cardiology, the Affiliated Hospital of Southwest Medical University, Luzhou, 646000, Sichuan, China.
Journal of cardiovascular translational research
|May 20, 2024
概括
糖携带载体蛋白抑制剂 (SGLTi) 在缺血性心脏病 (IHD) 中表现出保护作用. 这些新型低血糖药物通过调节各种生物机制,可能有利于IHD.
科学领域:
- 心脏病学 心脏病学
- 内分泌学 在内分泌学.
- 药理学 药理学是指药理学的学科.
背景情况:
- 缺血性心脏病 (IHD) 具有显著的发病率和死亡率.
- 糖携带载体蛋白抑制剂 (SGLTi) 是新兴的低血糖药物.
研究的目的:
- 审查SGLTi在缺血性心脏病 (IHD) 中的保护机制.
- 提供SGLTi作为IHD治疗策略的理论证据.
主要方法:
- 临床试验和动物实验的文献综述.
- 在IHD模型中分析SGLTi作用的拟议机制.
主要成果:
- SGLTi在心肌梗塞 (MI) 和缺血/反 (I/R) 损伤中表现出保护作用.
- 潜在的机制包括能量代谢,抗炎症,抗纤维化和血管生成.
结论:
- 在IHD中,SGLTi表现出多方面的保护作用.
- 对这些机制的进一步研究可以指导IHD治疗策略.
相关概念视频
Glucose Absorption Into the Small Intestine
31.6K
Complex carbohydrates consumed cannot be absorbed into the small intestine in their original form. First, they must be hydrolyzed to a monosaccharide form such as glucose or galactose. These monosaccharides are then transported across the intestinal membrane and into the blood via transcellular transport. The intestinal epithelial cells allow the movement of these monosaccharides with a defined 'entry' through membrane transporter proteins present on their apical membrane and...
31.6K
Glucose Transporters
22.7K
Glucose transporters facilitate the transport of glucose across the cell membrane. In addition to glucose, some glucose transporters can also aid the movement of other hexoses such as fructose, mannose, and galactose.
Facilitated diffusion-glucose transporters (GLUTs) are encoded by the solute-linked carrier (SLC) family 2, subfamily A gene family, or SLC2A. The 14 GLUT protein members are distributed into three classes:
Facilitated diffusion-glucose transporters (GLUTs) are encoded by the solute-linked carrier (SLC) family 2, subfamily A gene family, or SLC2A. The 14 GLUT protein members are distributed into three classes:
22.7K
Secondary Active Transport
7.0K
One example of how cells use the energy contained in electrochemical gradients is demonstrated by glucose transport into cells. The ion vital to this process is sodium (Na+), which is typically present in higher concentrations extracellularly than in the cytosol. Such a concentration difference is due, in part, to the action of an enzyme "pump" embedded in the cellular membrane that actively expels Na+ from a cell. Importantly, as this pump contributes to the high concentration of...
7.0K
Ischemic Heart Disease: Overview
1.3K
Ischemic heart disease occurs when the heart's blood supply dwindles, causing an ominous lack of oxygen and nutrients. This deficiency, stemming from reduced or obstructed blood flow, spells danger, leading to heart muscle damage and dysfunction.
Atherosclerosis, the primary malefactor, orchestrates this dangerous condition. It manifests as the accumulation of fatty deposits, akin to insidious plaques, within arterial walls. As time elapses, these plaques metamorphose, hardening and...
Atherosclerosis, the primary malefactor, orchestrates this dangerous condition. It manifests as the accumulation of fatty deposits, akin to insidious plaques, within arterial walls. As time elapses, these plaques metamorphose, hardening and...
1.3K
Dipeptidyl Peptidase 4 Inhibitors
181
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
181
Heart Failure Drugs: Inotropic Agents
570
Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
570

